2Youn YS, Lee KY, Hwang JY, et al. Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia [ J ]. BMC Pediatr, 2010,10:48.
3Cevey - Macherel M, Galetto - Lacour A, Gervaix A, et al. Etiology of community - acquired pneumonia in hospitalized children based on WHO clinical guidelines [ J ]. Eur J Pediatr, 2009,168 ( 12 ) : 1429 - 1436.
4Don M, Valent F, Korppi M, et al. Efficacy of serum procalcitonin in evaluating severity of community - acquired pneumonia in childhood [J]. Scand J Infect Dis, 2007,39(2) :129 -137.
5Berg P, Lindhardt BO. The role of procalcitonin in adult patients with community -acquired pneumonia- -a systematic review[ J]. Dan Med J, 2012,59(3) :A4357.
6Park JH, Wee JH, Choi SP, et al. The value of procaleitonin level in community - acquired pneumonia in the ED [ J ]. Am J Emerg Med, 2012,30(7) :1248 - 1254.
7Hsieh SC, Kuo YT, Chem MS, et al. Mycoplasma pneumonia : clinical and radiographic features in 39 children [ J ]. Pediatr Int, 2007,49 ( 3 ) : 363 - 367.
8Courtais C, Kuster N, Dupuy AM, et al. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score commu- nity acquired pneumonia[J]. Am J Emerg Med, 2013,31 ( 1 ) :215 - 221.
9Vervloet LA, Marguet C, Camargos PA. Infection by Myco- plasma pneumoniae and its importanee as an etiologieal agent in ehildhood eommunity-aequired pneumonias [J]. Braz J Infeet Dis, 2007, 11(5): 507-514.
